A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

细胞毒性T细胞 癌症研究 肿瘤微环境 抗体 抗原 癌症 体内 细胞毒性 免疫系统 免疫学 医学 药理学 生物 体外 内科学 生物化学 生物技术
作者
Leila M. Boustany,Sherry L. LaPorte,Laurie Wong,Clayton W. White,Veena Vinod,Joel Shen,Wendy Yu,David Koditek,Michael B. Winter,Stephen J. Moore,Mei Li,Linnea Diep,Yuanhui Huang,Shouchun Liu,Olga S. Vasiljeva,Jim West,Jennifer Hope Richardson,Bryan A. Irving,Marcia P. Belvin,W. Michael Kavanaugh
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (22): 4288-4298 被引量:67
标识
DOI:10.1158/0008-5472.can-21-2483
摘要

T cell-engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit and activate cytotoxic T cells to stimulate an antitumor immune response. However, the development of TCBs against solid tumors has been limited by significant on-target toxicity to normal tissues. Probody therapeutics have been developed as a novel class of recombinant, protease-activated antibody prodrugs that are "masked" to reduce antigen binding in healthy tissues but can become conditionally unmasked by proteases that are preferentially active in the tumor microenvironment (TME). Here, we describe the preclinical efficacy and safety of CI107, a Probody TCB targeting EGFR and CD3. In vitro, the protease-activated, unmasked CI107 effectively bound EGFR and CD3 expressed on the surface of cells and induced T-cell activation, cytokine release, and cytotoxicity toward tumor cells. In contrast, dually masked CI107 displayed a >500-fold reduction in antigen binding and >15,000-fold reduction in cytotoxic activity. In vivo, CI107 potently induced dose-dependent tumor regression of established colon cancer xenografts in mice engrafted with human peripheral blood mononuclear cells. Furthermore, the MTD of CI107 in cynomolgus monkeys was more than 60-fold higher than that of the unmasked TCB, and much lower levels of toxicity were observed in animals receiving CI107. Therefore, by localizing activity to the TME and thus limiting toxicity to normal tissues, this Probody TCB demonstrates the potential to expand clinical opportunities for TCBs as effective anticancer therapies for solid tumor indications. SIGNIFICANCE: A conditionally active EGFR-CD3 T cell-engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
德古完成签到,获得积分10
1秒前
111完成签到,获得积分10
1秒前
隐形曼青的应助被郭娅楠采纳,获得10
1秒前
2秒前
Liam要动脑发布了新的文献求助10
2秒前
禾木呈发布了新的文献求助10
2秒前
2秒前
3秒前
ding的应助被拼搏从灵采纳,获得10
3秒前
桐桐的应助被Lei采纳,获得10
3秒前
qh完成签到,获得积分10
4秒前
4秒前
852的应助被豪123采纳,获得10
4秒前
4秒前
4秒前
nwy发布了新的文献求助10
5秒前
5秒前
飞鱼完成签到,获得积分10
5秒前
6秒前
6秒前
UJS_2022发布了新的文献求助50
7秒前
123发布了新的文献求助10
8秒前
隐形曼青的应助被七七采纳,获得10
8秒前
9秒前
晓晓发布了新的文献求助10
10秒前
在水一方的应助被开朗念波采纳,获得10
11秒前
爆米花的应助被牧百川采纳,获得10
11秒前
anzhiyuan发布了新的文献求助10
11秒前
11秒前
朱彤发布了新的文献求助10
12秒前
13秒前
深情安青的应助被abcde采纳,获得10
13秒前
Jasper的应助被liang采纳,获得10
13秒前
13秒前
郭娅楠发布了新的文献求助10
15秒前
认真的紫寒完成签到,获得积分20
15秒前
16秒前
勇楚獭飞发布了新的文献求助20
16秒前
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184156
求助须知:如何正确求助?哪些是违规求助? 9573231
关于积分的说明 21830220
捐赠科研通 7781184
什么是DOI,文献DOI怎么找? 3434230
关于科研通互助平台的介绍 2558353
邀请新用户注册赠送积分活动 2480728